Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial
Research output: Contribution to journal › Letter › Research › peer-review
| Original language | English |
|---|---|
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 25 |
| Issue number | 10 |
| Pages (from-to) | 3064-3067 |
| Number of pages | 4 |
| ISSN | 1462-8902 |
| DOIs | |
| Publication status | Published - 2023 |
- clinical trial, diabetes complications, diabetic neuropathy, empagliflozin, linagliptin, SGLT2 inhibitor
Research areas
ID: 365814070